

[Open Peer Review on Qeios](#)

Rivoceranib

National Cancer Institute

Source

National Cancer Institute. *Rivoceranib*. NCI Thesaurus. Code C152237.

An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.